In the wake of the pandemic, public healthcare systems worldwide have faced challenges in recovery, especially with the growing elderly population in Western countries straining services like the NHS in the UK, which is frequently described as in crisis. Private companies, many utilizing technology, are seizing the opportunity in the market. Cera, a UK-based proprietary software platform and in-home healthcare provider, recently secured $150 million in funding through a mix of debt and equity, with a focus on scaling its AI-driven platform.
Cera’s previous funding round in 2022 totaled $320 million (£260 million), split evenly between equity and debt financing. The company has attracted 14 investors, including Earlymarket, Guinness Ventures, DigitalHealth. London Accelerator, and Robin Klein. Cera revealed that it achieved EBITA positivity in 2023 and became cashflow positive in 2024, positioning itself as a self-sustaining business that could raise significant debt funding.
Dr. Ben Maruthappu MBE, Founder & CEO of Cera, highlighted the company’s progress towards profitability, driven by its innovative use of technology and AI. Cera’s app enables carers to efficiently plan their work and track patient symptoms, leveraging AI to predict potential health risks and improve patient outcomes.
With more than $407 million raised in total, Cera faces competitors like Home Instead and Bluebird Care in the UK and Signify Health and CVS Health in the US. Maruthappu emphasized Cera’s role in providing comprehensive healthcare at home, easing the burden on NHS and expanding services to address various healthcare needs.
Cera’s data-driven approach has enabled it to develop predictive AI algorithms that significantly reduce falls, hospitalizations, and improve overall care outcomes. The company’s success has attracted the support of investors like BDT & MSD, who see great potential in Cera’s ability to deliver exceptional care through technology.
